FR2391M - - Google Patents
Download PDFInfo
- Publication number
- FR2391M FR2391M FR7585A FR67007585A FR2391M FR 2391 M FR2391 M FR 2391M FR 7585 A FR7585 A FR 7585A FR 67007585 A FR67007585 A FR 67007585A FR 2391 M FR2391 M FR 2391M
- Authority
- FR
- France
- Prior art keywords
- action
- product
- diuretic
- doses
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000001882 diuretic effect Effects 0.000 description 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- XAJCIJSHLSRMNK-UHFFFAOYSA-N 1,4-dihydrazinyl-1,4-dioxobutane-2-sulfonic acid Chemical compound NNC(=O)CC(S(O)(=O)=O)C(=O)NN XAJCIJSHLSRMNK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- -1 succinyl dimethyl ester sulfonate Chemical compound 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960003893 phenacetin Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7585A FR2391M (en:Method) | 1962-11-20 | 1962-11-20 | |
| BE639681A BE639681A (fr) | 1962-11-20 | 1963-11-08 | Nouveau médicament diurétique. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7585A FR2391M (en:Method) | 1962-11-20 | 1962-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2391M true FR2391M (en:Method) | 1964-04-10 |
Family
ID=8584064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7585A Expired FR2391M (en:Method) | 1962-11-20 | 1962-11-20 |
Country Status (2)
| Country | Link |
|---|---|
| BE (1) | BE639681A (en:Method) |
| FR (1) | FR2391M (en:Method) |
-
1962
- 1962-11-20 FR FR7585A patent/FR2391M/fr not_active Expired
-
1963
- 1963-11-08 BE BE639681A patent/BE639681A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE639681A (fr) | 1964-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6346278B1 (en) | Lipid extract having anti-inflammatory activity | |
| US4683242A (en) | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters | |
| Mudge et al. | Effect of acetate on the renal excretion of p-aminohippurate in the dog | |
| Palmer et al. | Electrophysiological response of cerebellar Purkinje neurons to leukotriene D4 and B4. | |
| JP2001503737A (ja) | 糖尿病の発生を防止するためのシブトラミン類似体の利用 | |
| JPH11509547A (ja) | Ｌ−ドーパエチルエステルの医薬組成品 | |
| JPH06199701A (ja) | 外用消炎鎮痛剤 | |
| CN107951869A (zh) | 含有大麻二酚的药物制剂及其应用 | |
| JP2014185132A (ja) | ロキソプロフェンを含有する医薬組成物 | |
| JPH04505758A (ja) | 即効で増強された解熱応答 | |
| NL8320239A (nl) | Verbeterde analgetische en ontstekingsremmende preparaten met daarin ibuprofen, alsmede werkwijze voor het gebruik daarvan. | |
| KR900012892A (ko) | 항-염증성 아릴 화합물 | |
| HU199293B (en) | Process for production of tepically applicable medical compositions suitable for treatment of peptical ulcus by mammates | |
| FR2391M (en:Method) | ||
| JPH05500361A (ja) | 開始―促進され／増強された解熱応答 | |
| EP0429360B1 (fr) | Inhibition du syndrome d'abstinence | |
| ES2343166T3 (es) | Activadores para el receptor activado por proliferador de peroxisoma. | |
| DE3785689T2 (de) | Verwendung von prostaglandin-biosynthese-hemmer. | |
| EP0342139B1 (fr) | Utilisation de l'Aspartate d'Arginine pour la fabrication d'un médicament pour traiter certains troubles de la mémoire | |
| JPS60120995A (ja) | 新規アミノ酸誘導体の製法 | |
| US3360434A (en) | Method for reducing blood pressure with phenylalanine derivatives | |
| POWER et al. | The detoxication of putrefactive products by the human body | |
| Diefenbach et al. | Digitoxin—A Critical Review | |
| Moxon | Toxicity of selenium‐cystine and some other organic selenium compounds | |
| FR2465481A1 (fr) | Compositions anti-ulcereuses a base d'acide 5-methoxy-2-methyl-3-indolyl-acethydroxamique |